

EDITORIAL

BOARD:

ADVISOR:

PN. NUR SHAZRINA
BT AHMAD

EDITOR:

CIK YEE CHIOU
YANN

CO-EDITORS:

EN AHMAD HAFIZI
NOH

CIK DARSIGA
SELVARAJAH

CIK PANISHA
NAGARATNAM

Di dalam isu
ini:

POMs 1

SODIUM 5

VALPROATE :
update on the risk of
abnormal
pregnancy outcomes

ADR CASES IN 6

HOSPITAL
SEGAMAT

TDM 8

SAMPLING
GUIDE

CROSSWORD 10

TDM

AKTIVITI 11

JABATAN
FARMASI

PATIENT'S OWN MEDICINES (POMs)

1. DEFINISI PATIENT'S OWN MEDICINES (POMs)

POMs adalah ubat-ubatan pesakit yang telah dipreskripsi atau dibeli sendiri oleh pesakit dan dibawa ke hospital semasa memerlukan rawatan di wad. Pesakit perlu membawa ubat-ubat mereka ke hospital supaya anggota kesihatan dapat mengenal pasti sejarah pengubatan yang tepat bagi memastikan kesinambungan penjagaan pesakit. Ubat komplementari

termasuk ubat tradisional dan suplemen adalah dikecualikan daripada POMs kerana kesukaran untuk mengenal pasti kandungan dan indikasinya.



2. MATLAMAT

Objektif polisi & garis panduan ini adalah untuk memberi panduan pengurusan POMs semasa

kemasukan pesakit ke dalam wad di fasiliti kesihatan KKM. Pengurusan POMs yang berkesan dapat mengoptimalkan penggunaan ubat dan mengelakkan pembaziran.


PRA KEMASUKAN WAD

Penerangan / risalah mengenai pelaksanaan Program POMs akan diberikan semasa pesakit berada di klinik / Jabatan Kecemasan.


REFERENCE:

PATIENT'S OWN MEDICATION BAHAGIAN PERKHIDMATAN FARMASI JOHOR. JABATAN KESIHATAN NEGERI JOHOR


POLISI POMs



PROSEDUR POMs



PEMBEKALAN POMs KETIKA DISCAJ



APPENDIX A	Loose tablet dalam botol	Ubat biji blister pack	Ubat krim dan suppository	Cecair	Insulin
Boleh digunakan	-Masih dalam bungkusan asal lengkap dengan butiran ubat	Info di blister pack: -Nama dan kekuatan ubat -Tarikh luput - N o m b o r batch	-Dalam pek asal -Belum tamat tempoh -Bersih	-Belum tamat tempoh / mempunyai tarikh buka - B e t u l penyimpanan -Simpan dalam botol asal	- D i b u k a kurang dari 28 hari
Dilarang guna	-Tiada maklumat lengkap	- T i a d a maklumat seperti yg di atas	-Sampai tarikh luput -Krim berubah warna -Bekas kotor/ rosak	-Tamat tarikh luput -Cara simpan tidak betul -Fizikal ubat berubah	- D i b u k a lebih dari 28 hari

AKTIVITI POMs DI HOSPITAL SEGAMAT



Taklimat diberikan kepada pakar, pegawai perubatan, anggota farmasi dan jururawat

SODIUM VALPROATE : update on the risk of abnormal pregnancy outcomes

Valproate is an effective medicine used to treat epilepsy and bipolar disorder.

Valproate can seriously harm an unborn child when taken during pregnancy. In women who take valproate, around 10 babies in every 100 will have birth defects.

Birth defects include *spina bifida* (where the bones of the spine are not properly developed); facial and skull malformations, heart, kidney, urinary tract and sexual organ malformation and limb defects.



You can help by reporting any side effects that you may get directly to the National Pharmaceutical Regulatory Agency (NPRA) through the website <http://npra.moh.gov.my>

RECOMMENDATIONS

Treatment should only be initiated if other treatments are ineffective or not tolerated.

The benefit and risk should be carefully reconsidered at regular treatment reviews.

Preferably sodium valproate

should be prescribed as monotherapy and at the lowest effective dose, if possible as a prolonged release formulation to avoid high peak plasma concentrations.

The daily dose should be divided into at least two single doses.

Reference:

https://npra.moh.gov.my/images/Circulars_Directive/Regulatory_Information/2016/161012_Direktif_Bil17_2016.pdf

What you must do if you are being prescribed valproate:

For women who are able to get pregnant, when taking valproate, always use reliable contraception so you do not have an unplanned pregnancy.

If you are thinking having a baby, speak to your doctor and do not stop using contraception until you have done so.

Tell your doctor at once if you think you may be pregnant or know you are pregnant. Never stop taking Valproate unless your doctor tells you to as your condition may become worst.






ADVERSE DRUG REACTION (ADR) CASES IN HOSPITAL SEGAMAT JAN TO DEC 2016

ALL suspected Adverse Drug Reactions (ADRs) should be reported to the National Centre for Adverse Drug Reactions Monitoring, including those for vaccines, cosmetics and traditional products.

In Hospital Segamat, 11 case reported in 2016. (1 pediatric case and 10 adult cases)

Total eight cases involved cutaneous reaction with one documented cases of Steven Johnson Syndroms and another documented cases of toxic epidermal necrosis.




The pharmacological classes of drug include antibacterial, antiviral, antifungal, neurology, rheumatology, ulcer healing drug, and antiemetic. Antipsychotics have the highest number of ADR event.

THERAPEUTIC DRUG MONITORING (TDM)

		TDM SERUM SAMPLING GUIDE														
		DRUG		STEADY STATE		SAMPLING TIME		SAMPLE STABILITY								
Analisa yang dijalankan di Jabatan Farmasi 1) Acetaminophen 2) Carbamazepine 3) Digoxin 4) Gentamicin 5) Phenobarbitone 6) Phenytoin 7) Salicylate 7) Sodium Valproate 8) Theophylline / Aminophylline 9) Vancomycin		AMI-NOG LYC OSID ES	AMIKACIN	SDD	MDD	SDD	MDD	-								
				Adult & Paed	Adult Pre & Post 4 th dose	1 st sample Post 2 hours	Pre 0-30 min before dose	8 hours								
			GEN-TAMICIN	After 2 nd dose	Paed Pre & Post 3 rd dose	2 nd sample post 6 hours	Post 60 min after 60 min infusion completed	4 hours								
				IP: before 3 rd bag		IP: pre (0-30 min before dose)										
Analisa yang dirujuk ke fasiliti luar 1) Amikacin 2) Cyclosporin 3) Lithium 4) Tacrolimus		CARBAMAZEPINE		Initiation: 2-3 weeks (Induction Phase) MD: 2-5 days after initiation and dose changes.		Pre: 0-30 min before dose		8 hours								
		CYCLOSPORINE (EDTA tube)		3-5 days		C0: Immediately before next dose C2: 2 hours after dose		8 hours								
		DIGOXIN		Withold LD: 7-14 days With LD: 12-24 hours ESRD: 15-20 days		Pre: 0-30 min before dose Post: Oral: at least 6 hours after dose IV: at least 4 hours after dose		8 hours								
		LITHIUM		4-5 days		Pre: 12 hours after dose (BD) Pre: 24 hours after dose (OD)		-								
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%;">Masa penerimaan sampel</th> <th style="width: 50%;">Masa penyediaan laporan bertulis</th> </tr> </thead> <tbody> <tr> <td>Ahad-Rabu: 8pg-3ptg</td> <td rowspan="2">Pada hari yang sama</td> </tr> <tr> <td>Khamis-Sabtu & Cuti Umum: 8pg-1ptg</td> </tr> <tr> <td>Ahad-Rabu: 3ptg-8pg</td> <td rowspan="2">Pada hari berikutnya</td> </tr> <tr> <td>Khamis-Sabtu & Cuti Umum: 1ptg-8pg</td> </tr> </tbody> </table>	Masa penerimaan sampel	Masa penyediaan laporan bertulis	Ahad-Rabu: 8pg-3ptg	Pada hari yang sama	Khamis-Sabtu & Cuti Umum: 8pg-1ptg	Ahad-Rabu: 3ptg-8pg	Pada hari berikutnya	Khamis-Sabtu & Cuti Umum: 1ptg-8pg		PARACETAMOL		Toxicity: 4 hours after ingestion		Toxicity: 4 hours after single acute ingestion OR Unknown ingestion time: 2 samples at 2 hours interval		8 hours
	Masa penerimaan sampel	Masa penyediaan laporan bertulis														
	Ahad-Rabu: 8pg-3ptg	Pada hari yang sama														
	Khamis-Sabtu & Cuti Umum: 8pg-1ptg															
	Ahad-Rabu: 3ptg-8pg	Pada hari berikutnya														
	Khamis-Sabtu & Cuti Umum: 1ptg-8pg															
	PHENOBARBITAL		Without LD: 2-3 weeks After LD: 2-3 hours after administration		Pre: 0-30 min before dose		8 hours									
	PHENYTOIN		With LD: 12-24 hours Without LD: 8-10 days		Pre: 0-30 min before dose		8 hours									
SALICYCLATE		Therapeutic: 5-7 days Toxicity: 4 hours after ingestion		Therapeutic: 1-3 hours after dose Toxicity: 4 hours after ingestion		8 hours										
TACROLIMUS (EDTA tube)		3-5 days		Pre: 0-30 min before dose		-										
THEOPHYLLINE / AMINOPHYLLINE		Adults: 2 days Children: 1-2 days Infants: 1-5 days Newborn: 5 days Premaure neonates: 6 days		Pre: 0-30 min before dose		8 hours										
VALPROIC ACID		2-4 days		Pre: 0-30 min before dose		2 days										
VANCOMYCIN		Normal renal function: After 3 rd dose Impaired renal function: After 1 st stat dose Continuous infusion: Take a sample after 12-24 hours after starting the continuous infusion		Trough level: 30 mins before dose Peak level: 1 hour after the infusion completed		4 hours										
References: i) Martindale 33th Ed 2002 ii) Basic Clinical Pharmacokinetic (Winter) 2004 iii) Drug Information Handbook 10 th Ed 2003 iv) British National Formulary, Vol 50 Sept 2005 v) Micromedex @ Healthcare Series Vol 130 2006 vi) Infectious Disease Society of America vii) Drug Doses, Frank Shann 16 th Ed 2014		SDD: Single daily dosing MDD: Multiple daily dosing LD: Loading dose MD: Maintenance dose														

CHALLENGE TIME: TDM CROSSWORDS



Across
 1. aminophylline
 3. digoxin
 4. digbind
 8. valproate
 9. vancomycin
 10. amikacin

Down
 1. acetaminophen
 2. carbamazepine
 5. phenytoin
 6. cyclosporine
 7. tacrolimus

Across

1. indicated for bradycardia in neonates
3. use ideal body weight
4. antidote for digoxin
8. steady state : 2 to 4 days
9. sample TDM after stat dose for esrf patient
10. aminoglycoside

Down

1. rummack matthew nomogram
2. auto-induction
5. michaelis-menten pharmacokinetics
6. cannot be centrifuge
7. EDTA tube

AKTIVITI JABATAN FARMASI HOSPITAL SEGAMAT



ANGGOTA FARMASI BERSAMA DR AMAN DI MAJLIS PERPISAHAN & PENGHARGAAN PENGARAH HOSPITAL SEGAMAT



PENGLIBATAN PEGAWAI FARMASI DALAM AKTIVITI KEMASYARAKATAN BERSAMA WARGA HOSPITAL SEGAMAT



KURSUS ORIENTASI ANGGOTA BARU JABATAN FARMASI HOSPITAL SEGAMAT 2017